RxDoctor Payments Data

Mojca Lorbar, MD

Cardiovascular Disease · Middletown, CTNPI 1881681187

Payments from drug & device makers

$729in general payments, 2019–2025

Across 37 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$143
  • Johnson & Johnson$109
  • Amgen$101
  • Sanofi-aventis U.S. LLC$66
  • Amarin Pharma, Inc.$64
  • Regeneron Healthcare Solutions, Inc.$54
  • plus $191 from 7 others

What the payments were for

  • Food & beverage$70797%
  • Education$223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$729 in reported general payments places this provider in the 35th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$191,152
Medicare patients
1,139
Services billed
2,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban559$689,051
XareltoRivaroxaban178$233,671
Repatha SureclickEvolocumab107$75,213
EntrestoSacubitril/Valsartan63$73,756
JardianceEmpagliflozin67$66,612
Praluent PenAlirocumab22$17,502
BrilintaTicagrelor15$14,274
Metoprolol Succinate388$6,410
Rosuvastatin Calcium373$4,810
Digoxin14$3,102
Valsartan141$2,936
Diltiazem 24hr Er (Cd)Diltiazem Hcl96$2,714
Ezetimibe114$2,669
Atorvastatin Calcium220$2,398
Amiodarone Hcl25$1,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$689,051559 claims
Johnson & JohnsonXarelto$109$233,671178 claims
NovartisEntresto$143$73,75663 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →